中国经济网北京1月19日讯长鸿高科（605008）(605008.SH)1月16日晚间发布关于收到中国证券监督管 理委员会宁波监管局行政监管措施决定书的公告。 经查，宁波长鸿高分子科技股份有限公司(以下简称"长鸿高科")存在以下违规行为： 一是内部控制不完善。公司销售管理、在建工程管理执行不到位、募集资金管理相关制度不健全，存在 部分销售发货日期早于销售合同签订日期，重大工程合同审批未按内部制度履行审议程序，未明确募集 资金使用分级审批权限等问题，不符合《企业内部控制基本规范》第六条、第三十条第一款、第三十六 条、《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》(证监会公告[2022]15号) 第四条的规定。 二是收入确认时点不恰当。公司存在部分收入确认单据不规范的情况，未谨慎判断商品控制权转移时 点，2024年半年度提前确认部分营业收入，导致公司2024年半年报信息披露不准确，不符合《会计基础 工作规范》第三十六条、第四十八条第二项、第七十四条、《企业内部控制基本规范》第三十一条第一 款、《企业会计准则第14号——收入》第四条第一款、《上市公司信息披露管理办法》(证监会令第182 号)第三 ...

Group 1 - Xianghe Industrial signed a contract worth 43.1041 million yuan with China Railway 15th Bureau, accounting for approximately 6.5% of the company's projected revenue for 2024 [1] - Dayu Water-saving's subsidiary won a bid for a project valued at 133 million yuan, with a construction period of 545 days [2] - China National Materials International's subsidiary signed a contract worth 299 million Canadian dollars for engineering design and procurement services [3] Group 2 - Baoland expects a net loss of approximately 75 million yuan for 2025, compared to a loss of 58.7224 million yuan in the previous year [4] - Changhong High-tech received an administrative regulatory decision due to inadequate internal controls and improper revenue recognition [5] - Debon Stock will be suspended from trading on January 21, 2026, pending a decision on its delisting [6] Group 3 - Haitai Technology anticipates a net profit increase of 226.86% to 323.97% for 2025, with an expected profit of 51.5 million to 66.8 million yuan [7] - Fushun Special Steel expects a net loss of 770 million to 870 million yuan for 2025, compared to a profit of 112 million yuan in the previous year [8] - Rejing Bio forecasts a net loss of 210 million to 230 million yuan for 2025, compared to a loss of 191 million yuan in the previous year [10] Group 4 - Sanyou Chemical expects a net profit of approximately 91 million yuan for 2025, a decrease of about 82% compared to the previous year [11] - Lianhuan Pharmaceutical received approval for clinical trials of a new drug for benign prostatic hyperplasia [12] - Samsung New Materials anticipates a net loss for 2025, indicating a decline in operational performance [13] Group 5 - Jinggong Technology expects a net profit increase of 36.1% to 70.13% for 2025, with an estimated profit of 200 million to 250 million yuan [14] - Zhongsheng Pharmaceutical's subsidiary signed a licensing agreement for the production and commercialization of RAY1225 injection, with total payments expected to reach 1 billion yuan [15] - Hengshuai shares saw a reduction of 600,000 convertible bonds held by its controlling shareholder [16] Group 6 - Buchang Pharmaceutical plans to repurchase shares worth 60 million to 120 million yuan for employee stock ownership plans [17] - Baike Bio expects a net loss of 220 million to 280 million yuan for 2025, marking a shift from profit to loss [18] - Weishi Electronics anticipates a net profit decrease of 53.27% to 61.61% for 2025, with expected profits of 21.49 million to 26.16 million yuan [19] Group 7 - China Automotive Research expects a net profit increase of 17.85% for 2025, with a projected profit of 1.06 billion yuan [20] - Hualan Biological's controlling shareholder raised the upper limit of its shareholding plan to 86.66 yuan per share [22] - Nasda anticipates a net loss for 2025, indicating a decline in financial performance [23] Group 8 - Haizheng Pharmaceutical received a warning letter from the Zhejiang Securities Regulatory Commission for financial data inaccuracies [24] - Mengguli received an administrative regulatory decision for accounting errors in its financial reports [25] - Zhongguancun's subsidiary received acceptance for a drug application for a heart-related treatment [26] Group 9 - Hosheng Silicon Industry was ordered to correct information disclosure violations by the Zhejiang Securities Regulatory Commission [27] - Meiteng Technology expects a net profit decrease of 22.4551 million to 28.5285 million yuan for 2025, a reduction of 55.21% to 70.14% [28] - Sanwei Co. received a warning letter for financial irregularities related to related party transactions [29] Group 10 - Ganyue Expressway expects a net profit increase of 3.18% for 2025, with a projected profit of 1.32 billion yuan [30] - Xinhang New Materials plans to acquire 51% of Hairete for 12.8826 million yuan [31] - China Software anticipates a net loss of 41 million to 49 million yuan for 2025, an improvement from the previous year's loss [32] Group 11 - Rongsheng Development expects a net loss for 2025, with losses not exceeding the previous year's audited net assets [33] - Northern Rare Earth anticipates a net profit increase of 117% to 135% for 2025, with expected profits of 2.176 billion to 2.356 billion yuan [34] - Energy-saving Wind Power received renewable energy subsidies totaling 1.507 billion yuan, a 122.74% increase from the previous year [35] Group 12 - Dongzhu Ecology expects a net loss of 935 million to 1.135 billion yuan for 2025, compared to a loss of 630 million yuan in the previous year [36] - Jingneng Real Estate anticipates a net loss of 986 million to 1.315 billion yuan for 2025, compared to a loss of 109 million yuan in the previous year [37] - Hailu Heavy Industry signed new orders worth 1.941 billion yuan for 2025, with total orders on hand amounting to 3.597 billion yuan [38] Group 13 - Dalian Thermal Power expects a net loss of 92 million to 112 million yuan for 2025, compared to a loss of 146 million yuan in the previous year [39] - Jiangsu Sop expects a net profit decrease of 52.99% to 62.4% for 2025, with profits projected between 8 million to 10 million yuan [40] - Lian Technology plans to initiate preparations for issuing H-shares and listing on the Hong Kong Stock Exchange [42] Group 14 - Zhenyang Development expects a net profit decrease of 58.13% to 64.94% for 2025, with profits projected between 67 million to 80 million yuan [43] - Sheneng Co. reported a 1.7% decrease in power generation for 2025, with total generation of 57.654 billion kWh [44] - XGIMI Technology's subsidiary received a development notification from a well-known domestic automotive manufacturer [45] Group 15 - Wanhua Chemical's MDI Phase II facility resumed production after maintenance [46] - Daqing Energy expects a net loss of 1 billion to 1.3 billion yuan for 2025, with a reduction in losses compared to the previous year [47]

证券代码：605008 证券简称：长鸿高科 公告编号：2026-002 宁波长鸿高分子科技股份有限公司 关于前期会计差错更正的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波长鸿高分子科技股份有限公司（以下简称"公司"）于 2026 年 1 月 16 日召开第三届董事会第二十四次会议审议通过了《关于前期会计差错更正的议 案》，同意公司按照《企业会计准则第 28 号—会计政策、会计估计变更和差错 更正》及中国证监会《公开发行证券的公司信息披露编报规则第 19 号—财务信 息的更正及相关披露》的相关规定和要求，对相关会计差错进行更正。公司本次 会计差错更正涉及 2024 年半年度财务报表。具体情况如下： 一、前期会计差错更正的原因 近期，公司收到中国证券监督管理委员会宁波监管局下发的行政监管措施决 定书〔2026〕2 号（以下简称"决定书")，决定书指出公司未谨慎判断商品控制 权转移时点，2024 年半年度提前确认部分营业收入，具体内容详见公司同日披 露于上海证券交易所网站的《关于收到中国证券监督管理委员会宁波监管局行政 ...

宁波长鸿高分子科技股份有限公司 关于前期会计差错更正后的财务报表及相关附注 宁波长鸿高分子科技股份有限公司（以下简称"公司"）于2026年1月16日召开 第三届董事会第二十四次会议审议通过了《关于前期会计差错更正的议案》，同意公 司按照《企业会计准则第28号—会计政策、会计估计变更和差错更正》及中国证监会 《公开发行证券的公司信息披露编报规则第19号—财务信息的更正及相关披露》的相 关规定和要求，对相关会计差错进行更正。公司本次会计差错更正涉及2024年半年度 财务报表。更正后的2024年半年度财务报表及相关附注具体情况如下： 一、更正后的财务报表 2024年半年度财务报告更正后的财务报表如下： （一）合并资产负债表 合并资产负债表 2024年6月30日 编制单位： 宁波长鸿高分子科技股份有限公司 （二）合并利润表 合并利润表 2024年1—6月 单位：元 币种：人民币 | 项目 | 附注 | 2024年半年度 | 2023年半年度 | | --- | --- | --- | --- | | 一、营业总收入 | | 1,553,112,119.06 | 676,330,061.49 | | 其中：营业收入 | ...

证券代码：605008 证券简称：长鸿高科 公告编号：2026-001 宁波长鸿高分子科技股份有限公司 关于收到中国证券监督管理委员会宁波监管局行政监管措 施决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波长鸿高分子科技股份有限公司（以下简称"公司"）及相关人员于近日 收到中国证券监督管理委员会宁波监管局（以下简称"宁波证监局"）下发的《中 国证券监督管理委员会宁波监管局行政监管措施决定书》（[2026]2 号）（以下 简称"《决定书》"），现将相关情况公告如下： 一、《决定书》的主要内容 宁波长鸿高分子科技股份有限公司、陶春风、白骅、胡龙双： 经查，宁波长鸿高分子科技股份有限公司(以下简称长鸿高科或公司)存在以 下违规行为: 一是内部控制不完善。公司销售管理、在建工程管理执行不到位、募集资金 管理相关制度不健全，存在部分销售发货日期早于销售合同签订日期，重大工程 合同审批未按内部制度履行审议程序，未明确募集资金使用分级审批权限等问 题，不符合《企业内部控制基本规范》第六条、第三十条第一款、第三十六条、 《上 ...

证券代码：605008 证券简称：长鸿高科 公告编号：2026-003 宁波长鸿高分子科技股份有限公司 关于发行股份、可转换公司债券及支付现金购买资产并募集 配套资金暨关联交易事项的进展暨无法在规定时间内发出 召开股东会通知的专项说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次交易的基本情况 宁波长鸿高分子科技股份有限公司（以下简称"公司"）拟通过发行股份、 可转换公司债券及支付现金的方式购买广西长科新材料有限公司 100%股权并向 不超过 35 名特定投资者发行股份募集配套资金（以下简称"本次交易"）。根 据《上市公司重大资产重组管理办法》《上海证券交易所股票上市规则》等相关 规定，经初步测算，本次交易预计构成重大资产重组且构成关联交易；本次交易 不会导致公司控股股东及实际控制人发生变更，不构成重组上市。 二、本次交易的历史披露情况 根据上海证券交易所相关规定，经公司申请，公司股票于 2025 年 7 月 8 日 开市起停牌，停牌时间不超过 10 个交易日，具体内容详见公司于 2025 年 7 月 8 日披露的 ...

长鸿高科公告称，公司及相关人员收到宁波证监局下发的行政监管措施决定书。公司存在内部控制不完 善、收入确认时点不恰当等违规行为，2024年半年度提前确认部分营业收入致半年报信息披露不准确。 董事长陶春风、董事会秘书白骅、时任财务总监胡龙双对上述行为承担主要责任。宁波证监局对公司责 令改正，对三人采取监管谈话措施并记入诚信档案。公司应30个工作日内提交整改报告，相关人员10个 工作日内接受谈话。 ...

长鸿高科公告称，拟通过发行股份、可转换债券及支付现金买下广西长科新材料有限公司100%股权， 并募集配套资金，预计构成重大资产重组及关联交易。公司股票于2025年停牌，7月21日复牌。截至公 告披露日，交易涉及资产的审计、评估等工作未完成，预计无法在2026年1月18日前发召开股东会通 知。公司将继续推进，待条件成熟重开董事会，交易实施存在不确定性。 ...

Group 1 - The Shanghai Composite Index is at 4108.66 points, slightly down by 0.42%, with a total trading volume of 23623.15 billion yuan [1] - A total of 43 A-shares have surpassed their annual line today, with notable stocks showing significant deviation rates including Guangming Real Estate at 8.90%, Shenyu Co. at 6.99%, and Keheng Co. at 6.61% [1] - The stocks that have just crossed the annual line with smaller deviation rates include Ruipu Biotech, Yingtai Biotech, and Shanghai Phoenix [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Guangming Real Estate: 10.09% increase, trading at 3.82 yuan, with a deviation rate of 8.90% [1] - Shenyu Co.: 11.58% increase, trading at 43.08 yuan, with a deviation rate of 6.99% [1] - Keheng Co.: 11.72% increase, trading at 14.11 yuan, with a deviation rate of 6.61% [1] - Other notable stocks with significant increases include: - Shanghai Ailuo: 5.92% increase, trading at 9.31 yuan, with a deviation rate of 5.53% [1] - Lingpai Technology: 11.44% increase, trading at 31.47 yuan, with a deviation rate of 3.93% [1]

Core Viewpoint - Changhong High-Tech plans to inject Guangxi Changke into its operations, raising questions about whether this move is driven by a need for new narratives or project fundraising. The company has over 10 billion yuan in investment projects but faces significant short-term financial pressure due to high debt levels and limited cash reserves. Notably, while revenue has rapidly increased, gross margins have significantly declined, prompting concerns about the authenticity of the underlying data [1][2][10]. Group 1: Acquisition and Financial Health - The acquisition of Guangxi Changke, a high-tech enterprise focused on specialty synthetic resin materials, is intended to enhance Changhong's profitability and market competitiveness. However, Guangxi Changke's financial performance remains weak, with projected revenues of 668 million yuan in 2023 and a net loss of 335.97 million yuan [5][6]. - Changhong High-Tech's financial situation is precarious, with short-term debts exceeding 1.5 billion yuan and long-term debts nearing 1.4 billion yuan, while cash reserves stand at only 402 million yuan [8][10]. - The company has significant capital expenditure needs, including a 6.3 billion yuan investment in a biodegradable materials project and a 50 billion yuan investment in a new materials industrial park [9][10]. Group 2: Revenue and Profitability Concerns - Changhong High-Tech's revenue has surged from 1.733 billion yuan in 2021 to an expected 3.634 billion yuan in 2024, yet net profits have plummeted, with a reported 84.34% decline in net profit for the first three quarters of 2023 [13][16]. - The company's gross margin has drastically decreased from over 20% before its IPO to just 7.86% in Q3 2025, raising questions about the sustainability of its revenue growth [16][17]. - The introduction of new trade business has contributed to revenue growth but at the cost of lower margins, indicating a potential risk in the quality of earnings [15][26]. Group 3: Customer Relationships and Related Party Transactions - Changhong High-Tech's major customers have shown volatility, with significant changes in customer relationships, including the cancellation of a major customer in early 2023 [19][21]. - The new major customer, Ningbo Yinzhou Bot Polymer New Materials Co., Ltd., appears to have connections with Changhong's controlling shareholder, raising concerns about the transparency of these transactions [21][24]. - The company has engaged in related party transactions without timely disclosure, which may violate regulatory requirements and further complicate its financial integrity [25].